VE303

In 2024, significant advancements in *C difficile* treatment included updates in vaccinations, studies on severity, prevention, recurrence, and the FDA-approved Rebyota for recurrent *C diff*. Research on mRNA vaccines and legal challenges for FMT distribution were highlighted, alongside studies on vancomycin susceptibility and new clinical trials for preventing recurrent *C diff* infections.

DelveInsight's 'Hepatic Encephalopathy Pipeline Insight, 2024' report details the clinical development scenario and growth prospects for Hepatic Encephalopathy treatments, covering 3+ key companies and 3+ therapies in various stages of development, including Xifaxan, Golexanolone, and VE-303. The report provides insights into mechanism of action, route of administration, and market dynamics.

DelveInsight's 'Clostridium Difficile Infections Pipeline Insight, 2024' report details 20+ companies developing 22+ therapies, including Vedanta Biosciences' VE303 in Phase 3 and Ferring Pharmaceuticals' REBYOTA® approved by FDA in 2022. The report covers clinical trials, mechanisms of action, and route of administration for emerging treatments.